• Wondering if Vertex Pharmaceuticals at US$434.31 is offering good value right now, or if the easy money has already been made.
• The stock is down 3.1% over the last week, 1.6% over the past month and 3.9% year to date, even though the 3 year and 5 year returns sit at 30.2% and 108.0% respectively.
• These moves are playing out against a backdrop of ongoing interest in large biotech companies, as investors continue to weigh long term product pipelines against current pricing. While day to day headlines can be noisy, the recent pullback has put more focus on whether the current share price fully reflects those long term prospects.
• On Simply Wall St’s valuation checks, Vertex Pharmaceuticals scores 5 out of 6. The next sections will walk through what different valuation approaches say about the stock and hint at an even richer way to think about valuation that comes at the end of this article.

Approach 1: Vertex Pharmaceuticals Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock could be worth by projecting the company’s future cash flows and discounting them back to today using a required rate of return.

For Vertex Pharmaceuticals, the model uses a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow stands at about $3.76b. Analysts have provided explicit forecasts for several years, for example a projected free cash flow of $4.65b in 2026 and $5.05b in 2027. Later years out to 2035 are extrapolated by Simply Wall St, reaching a projected $10.56b in 2035.

Bringing all these projected cash flows back to today’s dollars gives an estimated intrinsic value of $805.27 per share. Compared with the recent share price of $434.31, this implies the stock trades at about a 46.1% discount, based on the model’s projections and assumptions.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Vertex Pharmaceuticals is undervalued by 46.1%. Track this in your watchlist or portfolio, or discover 54 more high quality undervalued stocks.

Approach 2: Vertex Pharmaceuticals Price vs Earnings

For profitable companies, the P/E ratio is a useful shortcut because it links what you pay for the stock directly to the earnings it is generating today. Higher growth expectations and lower perceived risk usually justify a higher P/E, while lower growth and higher risk tend to pull a “normal” or “fair” P/E down.

Vertex Pharmaceuticals currently trades on a P/E of 25.41x. That is above the Biotechs industry average of 17.27x and below the peer group average of 40.00x. Simply Wall St also calculates a proprietary “Fair Ratio” for the stock of 25.96x, which is the P/E that would be expected given factors such as its earnings growth profile, industry, profit margins, market cap and risk characteristics.

This Fair Ratio can be more helpful than a simple peer or industry comparison because it adjusts for the specific mix of growth, risks and profitability that is unique to Vertex Pharmaceuticals, rather than assuming all biotechs or peers deserve the same multiple. Compared with the actual P/E of 25.41x, the Fair Ratio of 25.96x suggests the current valuation is close to what the model would expect.

Result: ABOUT RIGHT

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Vertex Pharmaceuticals Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so meet Narratives, a simple way to connect your view of Vertex Pharmaceuticals to numbers by telling a story about its future revenue, earnings and margins, linking that story to a forecast, then to a Fair Value that you can compare with the current price.

On Simply Wall St’s Community page, Narratives are available as an easy tool used by millions of investors, helping you decide whether Vertex Pharmaceuticals looks more attractive or less attractive to you by setting out assumptions and then showing whether your Fair Value sits above or below today’s share price.

Because Narratives refresh as new information like earnings, trial results or regulatory news is added, you are not locked into one view and can see how the Fair Value based on your story evolves alongside the stock price in real time.

For example, one investor might lean toward the more cautious side and anchor on a Fair Value close to US$330 per share, focusing on regulatory pressure, high treatment costs and execution risk. Another might align with a more optimistic view closer to US$641 per share that leans on cystic fibrosis leadership, nephrology progress and broader pipeline potential. Narratives allow you to place yourself clearly along that spectrum.

For Vertex Pharmaceuticals, here are previews of two leading Vertex Pharmaceuticals Narratives that may help you compare different perspectives:

Fair Value: US$641.00

Implied discount to this Fair Value vs last close: about 32.2% below that Fair Value

Revenue growth assumption: 15.7% a year

• Cystic fibrosis (CF) leadership is paired with newer products like ALYFTREK and JOURNAVX, which bullish analysts see as expanding the revenue base and supporting higher margins.
• Gene editing and cell therapy programs such as CASGEVY, plus kidney and diabetes assets, are expected to build long duration, higher margin revenue streams.
• This view leans on strong cash generation and a solid balance sheet to fund R&D and deals, with analysts using a 7.1% discount rate and a future P/E of 22.4x to reach a Fair Value of US$641.

Fair Value: US$414.06

Implied downside vs last close: about 4.9% above that Fair Value

Revenue growth assumption: 6.29% a year

• Regulatory pressure on drug pricing, high treatment costs and concentrated exposure to rare genetic diseases are seen as limiting pricing power and compressing margins.
• High R&D needs and growing competition in gene editing, cell therapy and small molecules introduce the risk that new products may not fully offset CF reliance.
• To support a Fair Value of about US$414, this view pairs more modest revenue growth with a higher 28.0x future P/E and a discount rate of 7.13%, and treats the stock as closer to fairly priced on these assumptions.

If you want to see how these stories are built out in full, including charts, detailed forecasts and risk sections, you can read the complete set of Narratives on Simply Wall St, compare where your own assumptions sit between them and track how the Fair Value updates as new data arrives.

Do you think there's more to the story for Vertex Pharmaceuticals? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.